Research Archive — Page 79 of 139
-
March 25, 2021
Forty-three percent of melanoma patients have chronic complications from immunotherapies
Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology. -
March 25, 2021
Team studies new use for pulmonary hypertension drug
An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered. -
March 23, 2021
Prostate cancer microenvironment
Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets. -
March 22, 2021
Chemo for cancer lowers dementia risk
Cancer chemotherapy lowered risk of Alzheimer’s disease and other neurocognitive disorders that disproportionately affect older people. -
March 18, 2021
Strength training for osteoarthritis
High-intensity strength training is not more effective than low-intensity training or educational efforts for reducing knee pain in patients with osteoarthritis. -
March 18, 2021
HIV, diabetes and immune cells in fat
In HIV-positive individuals with diabetes, immune cells in fat are more proinflammatory and cytotoxic and may represent a therapeutic target for diabetes. -
March 18, 2021
Study to assess allergic reactions to COVID vaccines
Vanderbilt University Medical Center is recruiting volunteers for a randomized controlled phase 2 clinical trial to help determine the prevalence of systemic allergic reactions (SARS) to the two-dose COVID-19 mRNA vaccines made by Pfizer-BioNTech and Moderna.